147 related articles for article (PubMed ID: 35924358)
1. Expert recommendations for the management of diabetic macular edema with intravitreal dexamethasone implant: A Turkish Delphi study.
Batıoğlu F; Yanık Ö; Saatçi AO; Eldem B; Akkın C; Afrashi F; Özdemir H; Menteş J; Güngör K; Karabaş L; Karaçorlu M; Demircan N; Koçak N; Kır N; Ünlü N; Avcı R; Arvas S; Dündar SO; Kadayıfçılar S; Kaynak S; Özdek Ş; Ovalı T
Eur J Ophthalmol; 2023 Jan; 33(1):398-407. PubMed ID: 35924358
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: A national Delphi consensus study.
Kodjikian L; Baillif S; Couturier A; Creuzot-Garcher C; Delyfer MN; Matonti F; Weber M
Eur J Ophthalmol; 2022 Sep; 32(5):2845-2856. PubMed ID: 34779302
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Decision Making for Treatment of Diabetic Macular Oedema with DEX Implant: a Consensus Paper].
Augustin AJ; Feltgen N; Haritoglou C; Hoerauf H; Maier MM; Mardin CY; Schargus M
Klin Monbl Augenheilkd; 2021 Jan; 238(1):73-84. PubMed ID: 31770786
[TBL] [Abstract][Full Text] [Related]
4. Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach.
Giovannini A; Parravano M; Ricci F; Bandello F
Eur J Ophthalmol; 2019 Jan; 29(1):82-91. PubMed ID: 29882421
[TBL] [Abstract][Full Text] [Related]
5. Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: Expert recommendations using a Delphi approach.
García Layana A; Adán A; Ascaso FJ; Cabrera F; Donate J; Escobar Barranco JJ; Peralta G; Reyes García R; Rodríguez Maqueda M; Ruiz-Moreno JM; Vinagre I;
Eur J Ophthalmol; 2020 Sep; 30(5):1042-1052. PubMed ID: 31291782
[TBL] [Abstract][Full Text] [Related]
6. Dexamethasone implants in patients with diabetic macular edema undergoing cataract surgery: Italian expert panel consensus statements.
Alessio G; Boscia F; Caporossi A; Panozzo G; Reibaldi M; Staurenghi G; Varano M; Bandello F
Eur J Ophthalmol; 2021 May; 31(3):1122-1127. PubMed ID: 32635762
[TBL] [Abstract][Full Text] [Related]
7. The 0.19-mg Fluocinolone Acetonide Implant for the Treatment of Diabetic Macular Edema: An Expert Consensus.
Kolomeyer AM; Eichenbaum DA; Kiernan DF; Suñer IJ; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):166-173. PubMed ID: 36944067
[TBL] [Abstract][Full Text] [Related]
8. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
Ozsaygili C; Duru N
Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
[TBL] [Abstract][Full Text] [Related]
9. Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey.
Yilmaz M; Citirik M; Rahmanlar H; Alkan A; Gursoz H
Rom J Ophthalmol; 2022; 66(4):304-309. PubMed ID: 36589330
[No Abstract] [Full Text] [Related]
10. Short-term outcomes of intravitreal dexamethasone in relation to biomarkers in diabetic macular edema.
Narnaware SH; Bawankule PK; Raje D
Eur J Ophthalmol; 2021 May; 31(3):1185-1191. PubMed ID: 32429696
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
[TBL] [Abstract][Full Text] [Related]
12. VISUAL OUTCOMES IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT IN ROUTINE CLINICAL PRACTICE.
Urbančič M; Gardašević Topčić I; Matović K
Acta Clin Croat; 2021 Dec; 60(4):602-608. PubMed ID: 35734494
[TBL] [Abstract][Full Text] [Related]
13. Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study.
Cho H; Choi KS; Lee JY; Lee D; Choi NK; Lee Y; Bae S
BMJ Open; 2019 Sep; 9(9):e030930. PubMed ID: 31542758
[TBL] [Abstract][Full Text] [Related]
14. Vision-Related Quality of Life Outcomes in the BEVORDEX Study: A Clinical Trial Comparing Ozurdex Sustained Release Dexamethasone Intravitreal Implant and Bevacizumab Treatment for Diabetic Macular Edema.
Aroney C; Fraser-Bell S; Lamoureux EL; Gillies MC; Lim LL; Fenwick EK
Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5541-5546. PubMed ID: 27768792
[TBL] [Abstract][Full Text] [Related]
15. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.
Busch C; Zur D; Fraser-Bell S; Laíns I; Santos AR; Lupidi M; Cagini C; Gabrielle PH; Couturier A; Mané-Tauty V; Giancipoli E; Ricci GD; Cebeci Z; Rodríguez-Valdés PJ; Chaikitmongkol V; Amphornphruet A; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Iglicki M; Rehak M;
Acta Diabetol; 2018 Aug; 55(8):789-796. PubMed ID: 29730822
[TBL] [Abstract][Full Text] [Related]
16. Early treatment with dexamethasone intravitreal implants in diabetic macular edema: Naïve versus refractory patients.
Bux AV; Fortunato F; Barone A; Russo V; Delle Noci N; Iaculli C
Eur J Ophthalmol; 2022 May; 32(3):1619-1626. PubMed ID: 34120496
[TBL] [Abstract][Full Text] [Related]
17. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.
Hatz K; Ebneter A; Tuerksever C; Pruente C; Zinkernagel M
Ophthalmologica; 2018; 239(4):205-214. PubMed ID: 29402873
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.
Augustin AJ; Kuppermann BD; Lanzetta P; Loewenstein A; Li XY; Cui H; Hashad Y; Whitcup SM;
BMC Ophthalmol; 2015 Oct; 15():150. PubMed ID: 26519345
[TBL] [Abstract][Full Text] [Related]
19. Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: Early versus late switch.
Ruiz-Medrano J; Rodríguez-Leor R; Almazán E; Lugo F; Casado-Lopez E; Arias L; Ruiz-Moreno JM
Eur J Ophthalmol; 2021 May; 31(3):1135-1145. PubMed ID: 32493065
[TBL] [Abstract][Full Text] [Related]
20. Postmarketing safety surveillance of dexamethasone intravitreal implant in the treatment of visual impairment due to diabetic macular edema in India.
Nair U; Gupta V; Sharma M; Joshi S; Sudhalkar A; Altangerel U; Bai Y;
BMC Ophthalmol; 2020 Oct; 20(1):405. PubMed ID: 33036583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
